Haemoctin (Human Coagulation Factor Viii)

Haemoctin is indicated for the management of bleeding episodes and peri‑operative prophylaxis in individuals with hemophilia A who have a documented deficiency of factor VIII. The product may also be used for routine prophylactic therapy to reduce the frequency of spontaneous joint and muscle bleeds.

• Treatment of acute hemorrhage in hemophilia A.
• Surgical or invasive procedure prophylaxis.
• Routine prophylaxis to prevent spontaneous bleeds.
• Management of breakthrough bleeding despite regular therapy.
• Use in patients with inhibitors under specialist guidance.

Adverse reactions reported with Haemoctin are generally consistent with other factor VIII concentrates and reflect the underlying infusion of a plasma‑derived protein. Patients should be monitored for both frequent and rare events during and after administration.

Common

• Mild fever or chills occurring shortly after infusion.
• Headache of mild to moderate intensity.
• Redness, warmth, or mild swelling at the injection site.

Serious

• Development of inhibitors (neutralizing antibodies) that reduce efficacy.
• Anaphylactic or severe allergic reactions, including rash, bronchospasm, or hypotension.
• Thromboembolic events such as deep vein thrombosis or pulmonary embolism.

Before initiating Haemoctin therapy, clinicians should assess patient history and laboratory parameters to minimize risks and ensure appropriate use. Specific precautions are recommended for certain clinical situations and patient populations.

• Verify factor VIII activity level and inhibitor status before each infusion.
• Administer only under supervision of a qualified hematology specialist.
• Monitor regularly for development of inhibitors during therapy.
• Adjust dosing in patients with significant hepatic or renal impairment.
• Avoid use in individuals with known hypersensitivity to any product component.
• Follow storage and handling instructions to preserve product stability.

Haemoctin may interact with other agents that affect hemostasis or immune response, and clinicians should review concomitant medications. Potential interactions are categorized based on the level of clinical concern.

Avoid

• Concurrent use of other factor concentrates without specialist guidance.
• Administration with high‑dose aspirin or non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk.

Use with caution

• Antifibrinolytic agents (e.g., tranexamic acid) when combined with factor VIII.
• Immunosuppressive therapies that may alter inhibitor development.
• Vaccines administered shortly before or after infusion.